<code id='A698280E52'></code><style id='A698280E52'></style>
    • <acronym id='A698280E52'></acronym>
      <center id='A698280E52'><center id='A698280E52'><tfoot id='A698280E52'></tfoot></center><abbr id='A698280E52'><dir id='A698280E52'><tfoot id='A698280E52'></tfoot><noframes id='A698280E52'>

    • <optgroup id='A698280E52'><strike id='A698280E52'><sup id='A698280E52'></sup></strike><code id='A698280E52'></code></optgroup>
        1. <b id='A698280E52'><label id='A698280E52'><select id='A698280E52'><dt id='A698280E52'><span id='A698280E52'></span></dt></select></label></b><u id='A698280E52'></u>
          <i id='A698280E52'><strike id='A698280E52'><tt id='A698280E52'><pre id='A698280E52'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          Wikipedia

          author:hotspot    - browse:87228
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge